Intellia Therapeutics Inc diskutieren
Intellia Therapeutics Inc
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
7,69 €
-4,25 %
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $33.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Chardan Capital from $60.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Bank of America Corporation from $36.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Barclays PLC from $24.00 to $14.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at HC Wainwright from $18.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for NTLA provided by MarketBeat
Neueste Beiträge
Roth_Capital in Gran Tierra Energy Inc. diskutieren